Atorvastatin: In-Vivo Synergy with Metronidazole as Anti-Blastocystis Therapy

키워드

참고문헌 (40)

1. Tan KS, "New insights on classification, identification, and clinical relevance of Blastocystis spp", Clin Microbiol Rev, 21, pp.639~665 (2008)[DOI]
2. Alfellani MA, "Variable geographic distribution of Blastocystis subtypes and its potential implications", Acta Trop, 126, pp.11~18 (2013)[DOI]
3. Stark D, "Irritable bowel syndrome: A review on the role of intestinal protozoa and the importance of their detection and diagnosis", Int J Parasitol, 37, pp.11~20 (2007)[DOI]
4. Gallagher PG, "Blastocystis hominis enteritis", Pediatr Infect Dis, 4, pp.556~557 (1985)[DOI]
5. Tsang TK, "Terminal ileitis associated with Blastocystis hominis infection", Am J Gastroenterol, 84, pp.798~799 (1989)
6. Mirza H, "A rapid, high-throughput viability assay for Blastocystis spp. reveals metronidazole resistance and extensive subtype dependent variations in drug susceptibilities", Antimicrob Agents Chemother, 55, pp.637~648 (2011)[DOI]
7. Stensvold CR, "Eradication of Blastocystis carriage with antimicrobials: reality or delusion", J Clin Gastroenterol, 44, pp.85~90 (2010)[DOI]
8. Tan KS, "Current views on the clinical relevance of Blastocystis spp", Curr Infect Dis Rep, 12, pp.28~35 (2010)[DOI]
9. Johnson PJ, "Metronidazole and drug resistance", Parasitology Today, 9, pp.183~186 (1993)[DOI]
10. Lemee V, "Metronidazole, albendazole susceptibility of 11 clinical isolates of Giardia duodenalis from France", J Antimicrob Chemother, 46, pp.819~821 (2000)[DOI]
11. Wang CY, "Pleiotropic effects of statin therapy: molecular mechanisms and clinical results", Trends Mol Med, 14, pp.37~44 (2008)[DOI]
12. Zhou Q, "Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy", Curr Pharm Des, 15, pp.467~478 (2009)[DOI]
13. Rodriguez C, "Statins normalize vascular lysyl oxidase down regulation induced by proatherogenic risk factors", Cardiovasc Res, 83, pp.595~603 (2009)[DOI]
14. Mirza H, "Statin pleiotropy prevents rho kinase-mediated intestinal epithelial barrier compromise induced by Blastocystis cysteine proteases", Cell Microbiol, 14, pp.1474~1484 (2012)[DOI]
15. Dagci H, "Protozoon infections and intestinal permeability", Acta Trop, 81, pp.1~5 (2002)[DOI]
16. Puthia MK, "Blastocystis ratti induces contactindependent apoptosis, F-actin rearrangement, and barrier function disruption in IEC-6 cells", Infect Immun, 74, pp.4114~4123 (2006)[DOI]
17. Jones WR, "The experimental infection of rats with Entamoeba histolytica with a method for evaluating the anti-amoebic properties of new compounds", Ann Trop Med Parasitol, 40, pp.130~140 (1946)[DOI]
18. Eida OM, "Evaluation of the nitric oxide activity against B.hominis in vitro and in vivo", J Egypt Soc Parasitol, 38, pp.521~536 (2008)
19. Parkar U, "Direct characterization of Blastocystis from feces by PCR and evidence of zoonotic potential", Parasitology, 134, pp.359~367 (2007)[DOI]
20. Yang LQ, "In vitro response of Blastocystis hominis against traditional Chinese medicine", J Ethnopharmacol, 55, pp.35~42 (1996)[DOI]
21. Shlim DR, "Is Blastocystis hominis a cause of diarrhea in travelers? A prospective controlled study in Nepal", Clin Infect Dis, 21, pp.97~101 (1995)[DOI]
22. Yoshikawa H, "PCR-based identification of zoonotic isolates of Blastocystis from mammals and birds", Microbiology, 150, pp.1147~1151 (2004)[DOI]
23. Haresh K, "Isolate resistance of Blastocystis hominis to metronidazole", Trop Med Int Health, 4, pp.244~277 (1999)
24. Becker S, "Efficacy of antiamebic drugs in a mouse model", Am J Trop Med Hyg, 84, pp.581~586 (2011)[DOI]
25. Penna-Coutinho J, "Antimalarial activity of potential inhibitors of Plasmodium falciparum lactate dehydrogenase enzyme selected by docking studies", PLoS One, 6, pp.e21237~ (2011)[DOI]
26. Moe KT, "Experimental Blastocystis hominis infection in laboratory mice", Parasitol Res, 83, pp.319~325 (1997)[DOI]
27. Coppens I, "Activity, pharmacological inhibition and biological regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in Trypanosoma brucei", Mol Biochem Parasitol, 69, pp.29~40 (1995)[DOI]
28. Soliman MF, "Antischistosomal action of atorvastatin alone and concurrently with medroxyprogesterone acetate on Schistosoma haematobium harboured in hamster: surface ultrastructure and parasitological study", Acta Trop, 93, pp.1~9 (2005)[DOI]
29. Cortez E, "Statins inhibit Toxoplasma gondii multiplication in macrophages in vitro", Int J Antimicrob Agents, 33, pp.185~186 (2009)[DOI]
30. Nishikawa Y, "Host cell lipids control cholesteryl ester synthesis and storage in intracellular Toxoplasma", Cell Microbiol, 7, pp.849~867 (2005)[DOI]
31. Li ZH, "Toxoplasma gondii relies on Both Host and Parasite Isoprenoids and Can Be Rendered Sensitive to Atorvastatin", PLoS Pathog, 9, pp.e1003665~ (2013)[DOI]
32. Parquet V, "Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria", Antimicrob Agents Chemother, 53, pp.2248~2252 (2009)[DOI]
33. Taoufiq Z, "Rho kinase inhibition in severe malaria: thwarting parasite induced collateral damage to endothelia", J Infect Dis, 197, pp.1062~1073 (2008)[DOI]
34. Bessoff K, "Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block C. parvum growth", Antimicrob Agents Chemother, 57, pp.1804~1814 (2013)[DOI]
35. Dinesh N, "Exploring Leishmania donovani 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) as a potential drug target by biochemical, biophysical and inhibition studies", Microb Pathog, 66, pp.14~23 (2014)[DOI]
36. Kumar GA, "Statin-induced chronic cholesterol depletion inhibits Leishmania donovani infection: Relevance of optimum host membrane cholesterol", Biochim Biophys Acta, 1858, pp.2088~2096 (2016)[DOI]
37. Pradines B, "Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum", Antimicrob Agents Chemother, 51, pp.2654~2655 (2007)[DOI]
38. Bienvenu AL, "Statins alone are ineffective in cerebral malaria but potentiate artesunate", Antimicrob Agents Chemother, 52, pp.4203~4204 (2008)[DOI]
39. Kobbe R, "Simvastatin treatment shows no effect on the incidence of cerebral malaria or parasitemia during experimental malaria", Antimicrob Agents Chemother, 52, pp.1583~1584 (2008)[DOI]
40. Savini H, "Atorvastatin as a potential antimalarial drug: in vitro synergy in combinational therapy with dihydroartemisinin", Antimicrob Agents Chemother, 54, pp.966~967 (2010)[DOI]

관련 논문AI추천